U.S. markets closed
  • S&P 500

    4,538.43
    -38.67 (-0.84%)
     
  • Dow 30

    34,580.08
    -59.71 (-0.17%)
     
  • Nasdaq

    15,085.47
    -295.85 (-1.92%)
     
  • Russell 2000

    2,159.31
    -47.02 (-2.13%)
     
  • Crude Oil

    66.22
    -0.28 (-0.42%)
     
  • Gold

    1,782.10
    +21.40 (+1.22%)
     
  • Silver

    22.45
    +0.17 (+0.76%)
     
  • EUR/USD

    1.1317
    +0.0012 (+0.10%)
     
  • 10-Yr Bond

    1.3430
    -0.1050 (-7.25%)
     
  • GBP/USD

    1.3235
    -0.0067 (-0.50%)
     
  • USD/JPY

    112.8000
    -0.4090 (-0.36%)
     
  • BTC-USD

    49,209.27
    -3,329.09 (-6.34%)
     
  • CMC Crypto 200

    1,367.14
    -74.62 (-5.18%)
     
  • FTSE 100

    7,122.32
    -6.89 (-0.10%)
     
  • Nikkei 225

    28,029.57
    +276.20 (+1.00%)
     

Palatin Reports Financial Results for the Third Fiscal Quarter of 2021 and Provides Corporate Update

  • Oops!
    Something went wrong.
    Please try again later.
·10 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

-- Phase 3 Clinical Study of PL9643 in Patients with Dry Eye Disease Planned for Second Half Calendar 2021

-- Phase 2 Clinical Study of PL8177 in Patients with Ulcerative Colitis Planned for Second Half Calendar 2021

-- Vyleesi Gross Product Sales Up 89%, Net Revenue Up 154%, Prescriptions Increased 24% Compared to Prior Quarter

-- $68.6 Million in Cash and Cash Equivalents as of March 31, 2021

-- Teleconference and Webcast to be Held Today at 11:00 AM ET

CRANBURY, N.J., May 17, 2021 /PRNewswire/ -- Palatin (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, today announced results for its third fiscal quarter ended March 31, 2021.

Palatin Technologies, Inc.
Palatin Technologies, Inc.

"I am excited with Palatin's evolution and development advancements utilizing our proprietary melanocortin agonists to treat patients with inflammatory and autoimmune conditions," stated Carl Spana, Ph.D., President and CEO of Palatin. "We are hosting a KOL webinar on May 21st to introduce our growing portfolio of melanocortin agonists to treat the harmful effects of inflammation in the eye. On the clinical front, we are targeting to commence a Phase 3 trial of PL9643 in patients with dry eye disease in the second half of calendar year 2021. The emerging profile of PL9643, with its rapid therapeutic onset and excellent tolerability profile, is a potentially distinct advantage over commercially available dry eye therapies. In addition, we are targeting to commence a Phase 2 study with an oral formulation of PL8177 in ulcerative colitis patients in the second half of calendar year 2021."

"I am also pleased with the progress we have made with the Vyleesi program," continued Spana. "Our quarter ended March 31, 2021 reflected significant increases in gross sales, net sales, prescriptions, and insurance coverage over the prior quarter."

Business Highlights and Updates

  • Anti-Inflammatory / Autoimmune Programs

  • Vyleesi® (bremelanotide injection) / Hypoactive Sexual Desire Disorder (HSDD)

Third Quarter 2021 Results
Total net revenues, consisting of net product revenues of Vyleesi, were $88,741. There was no revenue reported for the third quarter of 2020.

  • Vyleesi gross sales amounted to $1,780,020, with net product revenue of $88,741, net of allowances and accruals, compared to gross sales for the prior quarter ended December 31, 2020 of $943,950, with net product revenue of $(163,971), net of allowances and accruals.

Total operating expenses were $6.6 million, compared to $5.7 million for the same period in 2020. The increase was mainly due to commercial expenses related to Vyleesi.

Palatin's net loss was $(5.7) million, or $(0.02) per share, compared to a net loss of $(5.4) million, or $(0.02) per share, for the comparable quarter of 2020.

As of March 31, 2021, the Company had $68.6 million in cash and cash equivalents and $1.9 million in accounts receivable, compared to $82.9 million in cash and cash equivalents and no accounts receivable as of June 30, 2020, with no outstanding debt.

Conference Call / Webcast
Palatin will host a conference call and audio webcast on May 17, 2021 at 11:00 a.m. Eastern Time to discuss the quarter ended March 31, 2021 results of operations in greater detail and provide an update on corporate developments. Individuals interested in listening to the conference call live can dial 1-866-248-8441 (US/Canada) or 1-856-344-9206 (international), conference ID 6765353 The audio webcast and replay can be accessed by logging on to the "Investor/Webcasts" section of Palatin's website at http://www.palatin.com. A telephone and audio webcast replay will be available approximately one hour after the completion of the call. To access the telephone replay, dial 1-888-203-1112 (US/Canada) or 1-719-457-0820 (international), passcode 6765353. The webcast and telephone replay will be available through May 24, 2021.

About Palatin
Palatin is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, with targeted, receptor-specific product candidates for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin's website at www.palatin.com.

Forward-looking Statements
Statements in this press release that are not historical facts, including statements about future expectations of Palatin technologies, Inc., such as statements about market potential of Vyleesi and other Palatin products in development, clinical trial results, potential actions by regulatory agencies including the FDA, regulatory plans, development programs, proposed indications for product candidates, market potential for product candidates, and potential adverse impacts due to the global COVID-19 pandemic such as delays in regulatory review, manufacturing and supply chain interruptions, adverse effects on healthcare systems and disruption of the global economy, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. Palatin intends that such forward-looking statements be subject to the safe harbors created thereby. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause Palatin's actual results to be materially different from its historical results or from any results expressed or implied by such forward-looking statements. Palatin's actual results may differ materially from those discussed in the forward-looking statements for reasons including, but not limited to, Palatin's ability to establish and maintain the capability for manufacturing, marketing and distribution of Vyleesi, sales of Vyleesi in the United States and elsewhere in the world, results of clinical trials, regulatory actions by the FDA and other regulatory and the need for regulatory approvals, Palatin's ability to fund development of its technology and establish and successfully complete clinical trials, the length of time and cost required to complete clinical trials and submit applications for regulatory approvals, products developed by competing pharmaceutical, biopharmaceutical and biotechnology companies, commercial acceptance of Palatin's products, and other factors discussed in Palatin's periodic filings with the Securities and Exchange Commission. Palatin is not responsible for updating for events that occur after the date of this press release.

Vyleesi® is a registered trademark of Palatin.









PALATIN TECHNOLOGIES, INC.

and Subsidiary

Consolidated Statements of Operations

(unaudited)










Three Months Ended March 31,


Nine Months Ended March 31,


2021


2020


2021


2020









REVENUES








Product revenue, net

$ 88,741


$ -


$ (363,790)


$ -

License and contract

-


-


-


117,989


88,741


-


(363,790)


117,989









OPERATING EXPENSES








Cost of products sold

55,440


-


110,040


-

Research and development

2,509,490


3,641,250


9,444,759


10,026,363

Selling, general and administrative

4,010,055


2,072,032


11,386,574


6,308,567

Gain on license termination agreement

-


-


(1,623,795)


-

Total operating expenses

6,574,985


5,713,282


19,317,578


16,334,930









Loss from operations

(6,486,244)


(5,713,282)


(19,681,368)


(16,216,941)









OTHER INCOME (EXPENSE)








Investment income

2,834


331,285


19,769


1,101,921

Foreign currency gain

753,750


-


8,748


-

Interest expense

-


(278)


(9,360)


(11,831)

Total other income (expense), net

756,584


331,007


19,157


1,090,090

NET LOSS

$ (5,729,660)


$ (5,382,275)


$(19,662,211)


$ (15,126,851)









Basic and diluted net loss per common share

$ (0.02)


$ (0.02)


$ (0.08)


$ (0.06)









Weighted average number of common shares outstanding used
in computing basic and diluted net loss per common share

236,832,283


235,322,087


236,525,514


234,449,813









PALATIN TECHNOLOGIES, INC.

and Subsidiary

Consolidated Balance Sheets

(unaudited)






March 31, 2021


June 30, 2020

ASSETS




Current assets:




Cash and cash equivalents

$ 68,641,312


$ 82,852,270

Accounts receivable

1,869,120


-

Inventories

6,114,718


-

Prepaid expenses and other current assets

2,760,242


738,216

Total current assets

79,385,392


83,590,486





Property and equipment, net

107,376


140,216

Right-of-use assets

1,322,326


1,266,132

Other assets

56,916


56,916

Total assets

$ 80,872,010


$ 85,053,750





LIABILITIES AND STOCKHOLDERS' EQUITY




Current liabilities:




Accounts payable

$ 864,012


$ 715,672

Accrued expenses

5,197,759


2,899,097

Short-term operating lease liabilities

347,070


312,784

Other current liabilities

3,628,000


-

Total current liabilities

10,036,841


3,927,553





Long-term operating lease liabilities

986,175


953,348

Other long-term liabilities

6,972,832


-

Total liabilities

17,995,848


4,880,901





Stockholders' equity:




Preferred stock of $0.01 par value – authorized 10,000,000 shares; shares
issued and outstanding designated as follows:




Series A Convertible: authorized 264,000 shares: issued and outstanding
4,030 shares as of March 31, 2021 and June 30, 2020

40


40

Common stock of $0.01 par value – authorized 300,000,000 shares:




issued and outstanding 230,049,691 shares as of March 31, 2021 and
229,258,400 shares as of June 30, 2020

2,300,497


2,292,584

Additional paid-in capital

398,436,738


396,079,127

Accumulated deficit

(337,861,113)


(318,198,902)

Total stockholders' equity

62,876,162


80,172,849

Total liabilities and stockholders' equity

$ 80,872,010


$ 85,053,750





Cision
Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/palatin-reports-financial-results-for-the-third-fiscal-quarter-of-2021-and-provides-corporate-update-301292101.html

SOURCE Palatin Technologies, Inc.